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Autologous Stem Cell Collection for the Treatment of
Malignant Diseases in Pediatric Patients: The Use of the
Power Hickman
Mollie Mulberry 1, David Margolis 2, Rowena C. Punzalan 3,
Michael Kelly 4, Meghen Browning 4. 1 Pediatric Hematolgy/
Oncology/Transplant, Medical College of Wisconsin,
Milwaukee, WI; 2 Children's Hospital, Medicial College of
Wisconsin, Milwaukee, WI; 3 Pediatric Hematology/Oncology,
Blood Center of Wisconsin, Milwaukee, WI; 4Medical College of
Wisconsin, Milwaukee, WI
Background: Dual-use catheters for chemotherapy and
hematopoetic progenitor cell collection are increasingly used
in the pediatric autologous transplant population. Published
data for beneﬁts and complications with these lines is
limited. We evaluated the use of various collection line
strategies before and after an institutional change to the
Power Hickman dual-use line to determine advantages and
disadvantages.
Methods: We reviewed 65 collection episodes over a 5 year
period comparing 3 groups: Power Hickman, Muhurkar
dialysis catheter, and peripheral IV. We assessed variables in
the categories of efﬁciency, complications, and cost.
Results: The Power Hickman was found to be more efﬁcient
than the Muhurkar for several variables including need for
second anesthesia for line placement and number of collec-
tion days. No differences were found among the groups for
complications. A cost advantagewas suggested for the Power
Hickman and PIV over the Muhurkar.
Discussion: A dialysis catheter may still be required for some
patients due to their size and other variables. However, for
other groups, our data indicate that dual-use catheters are
a safe and efﬁcient option.
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Malignancies
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Recurrence of hematological malignancies is one of the
most common indications for a second hemotopoeitic stem
cell transplant (HSCT). However there are limited outcomes
data after second HSCT in pediatric patients. We report the
results of second HSCT in 42 patients with relapsed lymphoid
(n-12) or myeloid (n-30) malignancies after ﬁrst HSCT per-
formed at our institution between 2000-2012. The median
age at the time of the second transplant was 7 years (range:
2-19 years). 20/42 patients had active disease at the time of
second transplant. The median time to relapse after a ﬁrst
transplant was 242 days (range: 138d-731d) for lymphoid
malignancies and 202.5days (range: 50d-1687d) for myeloid
malignancies. 20/42 received a haplo-identical donor
(haplo), 19/42 received a matched or mismatched unrelated
donor (MUD/MMUD) and 3/42 received a matched or mis-
matched related donor (MRD/MMRD). 16 patients had
myeloablative conditioning and 26 reduced intensityconditioning. Overall survival and disease free survival (DFS)
were 30% (13/42) and 26% (11/42), respectively with
a median follow up of 1496 days (range: 37d-3434d). 5/16 of
these survivors had received myeloablative conditioning
versus 6/26 who received reduced intensity conditioning.
The DFS by disease typewas 16% (2/12) for lymphoid and 30%
(9/30) for myeloid malignancies (MDS/AML, n¼6/10; AML,
n¼2/17; biphenotypic, n¼1/1), respectively. Patients with
MDS/AML had better outcome than patients with AML alone.
Survival also varied according to donor type (7/20 haplo, 4/19
MUD/MMUD, and 0/3 MRD/MMRD). Of the 11 disease free
survivors, 8 were in remission at the time of the second
transplant and 9 had relapsed >240 days post transplant.
Overall median survival was 4.6 years (range: 0.2-9.7 years).
The primary cause of death was relapse/persistent disease in
24/42 or infection/ GVHD in 7/42. Additionally, 7 of these
patients underwent a third HSCT for relapsed disease after
second HSCT and all 7 had active disease at time of third
transplant. No patients survived after a third transplant.
Hence 26% of relapsed patientsmay be long term disease free
survivors after a second HSCT from a haploidentical or
unrelated donor. Patients transplanted in full remission with
relapse >240 days after ﬁrst HSCT and a diagnosis of MDS/
AML are likely to be favorable prognostic factors.283
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Graft failure is an uncommon but serious complication
after allogeneic haematopoeitic stem cell transplantation
(HSCT) and is an indication for a 2nd HSCT. However, there
are limited outcomes data for pediatric patients who
undergo such therapy. We now report on 44 pediatric
patients who had a 2nd HSCT after graft failure following
HSCT for malignant (n¼14) or non-malignant diseases
(n¼30) at our institution between 2000-2012. Primary graft
failure was deﬁned as failure to achieve ANC >0.5x10 9 /L for
3 consecutive days by day +30 (day +42 for cord donors) or
donor chimerism <5% (n¼22) and secondary graft failure
was deﬁned as loss of chimerism to <5% after having ach-
ieved >5%, or ANC persistently below 0.5x10 9 /L or platelet
count <20 x109/L (n¼23). The median age at ﬁrst transplant
was 6 yrs (range 1month to 21 years), 18 pts were trans-
planted from a matched or mismatched unrelated donor
(MUD/MMUD); 16pts from haplo-identical donor (haplo),
and 10 from a matched or mismatched related donor (MRD/
MMRD). Donor stem cell products were: marrow for 26
patients; peripheral blood (PB) for 17 patients and a cord
blood unit (CBU) for 1 patient. 26 patients received mye-
loablative conditioning (MAC); 17 reduced-intensity condi-
tioning (RIC) and 1 patient received no conditioning. The
median time between 1st and 2nd HSCT was 55 days (range:
30d-2587d) for patients with malignancies and 66 days
(range: 33d-1846d) for patients with non-malignant disor-
ders. The donor was the same for both the 1st and 2nd
transplant for 34 pts. More patients received PB stem cell
products for their second transplant (marrow product¼17,
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MAC and 12 had no conditioning. 31 patients engrafted after
the 2nd HSCT. The overall survival for patients who under-
went a 2nd HSCT was 61% (27/44) with a median overall
survival of 3.8 years (range: 0.2yrs to >10 yrs) and better
survival for patients with non-malignant (21/30) versus
malignant disease (6/14). There was no difference in survival
between patients with primary versus secondary graft fail-
ures. Infection was the primary cause of death (9/17). For 13
patients who failed to engraft after 2nd HSCT, 3 patients died
and 10 patients received a 3rd HSCT of whom 5 patients
survive. Thus 61% of pediatric patients can achieve graft
salvage from a second transplant, and half of the continuing
graft failures can be rescued by a third HSCT.284
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Several studies have demonstrated that a therapeutic
Cyclosporine (CsA) concentration within one week following
graft infusion correlates with a reduced risk of grade III-IV
acute graft versus host disease (aGVHD). Therefore, to begin
a quality improvement (QI) project we performed a retro-
spective chart analysis to determine when, using our stan-
dard approach to initial CsA dosing, our allogeneic bone
marrow transplant patients ﬁrst achieved therapeutic CsA
levels (Trough¼150-250ng/ml). Fifty three allogeneic trans-
plants were performed during the period assessed, of which
47 were eligible for evaluation. Patients were excluded from
analysis due to alternate GVH prophylaxis or major drug
interactions. In this historical cohort, CsA prophylaxis was
initiated as follows: loading with Cyclosporine, 2mg/kg/dose
IV Q 12 hrs for two days (day -2 and day-1) then decreasing
to 1.5mg/kg/dose IV Q 12 hrs. Using this approach, 34% of
patients had therapeutic levels within the ﬁrst 3 days
following transplant. Following this baseline analysis, we
initiated a QI intervention aimed at achieving a therapeutic
trough CsA level in at least 80% of patients by Day +3. To
accomplish this, the following new CsA regimen was insti-
tuted. Patients 5 years or older received Cyclosporine at
2.5mg/kg/dose IV Q 12 hrs beginning on day -3, and patients
less than 5 years of age received Cyclosporine at 2.5mg/kg/
dose IV Q 8 beginning on day -3. If the trough level was
subtherapeutic (below 100 NG/ML) on day 0, we gave an
extra 2mg/kg/loading dose IV, then increased the basal dose
by20%. If the level was between 100 and 149, we increased
the basal dose by 20% without an additional loading dose.
The impact of this intervention on the percentage of patientsachieving therapeutic CsA levels between Day 0 and Day + 3
was then assessed. To date, we have performed 28 trans-
plants under the new CsA regimen. Of these, 23 patients
were evaluable. Five patients were excluded per the previous
criteria. Using the new dosing guidelines, 87% of patients
achieved therapeutic CsA levels in the Day 0 to Day +3
window. This represent a statiscally signiﬁcant improvement
over our previous dosing regimen in which 34% of patients
achieved therapeutic CsA levels by Day +3 (P < .0003). No
patients had supratherapeutic CsA levels, deﬁned as greater
than 400 ng/ml within the ﬁrst 3 days post transplant. One
patient did exhibit nephrotoxicity, deﬁned as a persistent
doubling of the serum creatinine by Day +10. This patient
also had Adeno and BK viruria at Day 0 which confounds
assessment of causation. Overall, the revised dosing regimen
is both well tolerated and more effective in achieving the
targeted CsA level in 80% of cases (95% conﬁdence interval,
68-95%). Following completion of this project, we plan
further analyses to determine whether this practice change
has impacted rates of aGVHD in our patient population.285
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In adults, hepatic complications following allogeneic
hematopoietic stem cell transplantation (AlloHSCT) are
associated with signiﬁcant morbidity and transplant related
mortality (TRM). However, there is a paucity of parallel data
on the incidence of, and risk factors for, liver injury (LI) and
the impact of LI on TRM in pediatric AlloHSCT recipients.
Methods: We compared total bilirubin, direct bilirubin and
alanine aminotransferase values pre-AlloHSCT and at
1month, day +100 and 12 months post-AlloHSCT in 248
patients following myeloablative conditioning (MAC) or
reduced toxicity/reduced intensity conditioning (RTC/RIC).
Liver injury was deﬁned as  Grade 2 toxicities according to
the NCI CTCAE 3.0/4.0 or total bilirubin 1.95mg/dL (1.5 times
above upper limit of normal). Univariate and multivariate
logistic regression models were used to identify risk factors
for the incidences of LI and TRM.
Results: 248 eligible patients received MAC (n¼109) or RTC/
RIC AlloHSCT (n¼139). The incidence of LI at 1 month post-
AlloSCT was signiﬁcantly higher in MAC vs. RTC/RIC
AlloHSCT based on total bilirubin levels (21.9% vs. 7.8%; P ¼
.0067). There was no signiﬁcant difference in LI pre-
AlloHSCT, LI at day +100 and 12 months post-AlloHSCT
between the two groups. The TRM among patients with LI at
1 month post-AlloHSCT was as 64.2% (CI95 49%, 79.4%)
